IL15

Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Solid Tumors in Oral Presentation at the 2024 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Obsidian, ICI, ASCO, TIL, Annual general meeting, Therapy, IL2, Patient, IL15, Society, Safety, Pharmaceutical industry

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced two presentations, including an oral presentation on the Phase 1 first-in-human study of OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma ( NCT05470283 ), at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago on May 31–June 4.

Key Points: 
  • Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced two presentations, including an oral presentation on the Phase 1 first-in-human study of OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma ( NCT05470283 ), at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago on May 31–June 4.
  • Title: OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma.
  • Title: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors.

Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Retrieved on: 
Friday, December 22, 2023
Gene, Research and development, SNTI, Food, IND, NOT, FDA, SAN, Doctor of Philosophy, Clinical trial, Cancer, FLT3, Patient, Acute myeloid leukemia, Safety, CD33, Development, AML, Synthetic biology, IL15

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies while sparing healthy bone marrow cells.

Key Points: 
  • The dose finding trial will evaluate two dose levels, either 1 or 1.5 billion SENTI-202 cells, administered after lymphodepleting conditioning in adult patients with relapsed or refractory (r/r) CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia (AML).
  • “Clearance of our IND application for SENTI-202 is a tremendous milestone and marks an important achievement for Senti as we transition to a clinical-stage therapeutics company,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
  • Senti Bio believes this approach can lead to more effective and durable responses in patients.
  • Through Senti Bio’s previously announced agreement with GeneFab, the Company has prepaid the majority of manufacturing-related expenses through the completion of the Phase 1 trial.

Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, Therapy, ICI, RECIST, University, National Resilience Institute, Disease, Patient, IL15, Monroe Dunaway Anderson, Neoplasm, DCR, ORR, Melanoma, IL2, CTMC, MD Anderson Cancer Center, TIL, Pharmaceutical industry, Obsidian

OBX-115 is an investigational novel IL2-sparing engineered TIL cell therapy armed with pharmacologically regulatable membrane-bound IL15 designed to enhance persistence, anti-tumor activity, and clinical safety of TIL cell therapy relative to unengineered TIL therapy plus high-dose IL2.

Key Points: 
  • OBX-115 is an investigational novel IL2-sparing engineered TIL cell therapy armed with pharmacologically regulatable membrane-bound IL15 designed to enhance persistence, anti-tumor activity, and clinical safety of TIL cell therapy relative to unengineered TIL therapy plus high-dose IL2.
  • , professor of Melanoma Medical Oncology and principal investigator of the study at The University of Texas MD Anderson Cancer Center.
  • “The OBX-115 data show its potential to be a meaningful advancement in the treatment of metastatic melanoma and TIL cell therapy,” said Parameswaran Hari, M.D., M.S., Chief Development Officer of Obsidian Therapeutics.
  • “These positive results underscore the potential for OBX-115 TIL cell therapy to offer patients with metastatic melanoma a differentiated TIL therapy without the need for IL2,” said Madan Jagasia, M.D., M.S., CEO of Obsidian Therapeutics.

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

Retrieved on: 
Wednesday, May 24, 2023
ICST, David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, IL15, Failure, Gene, Prostate cancer, Half-life, ISCT, NK, Toxicity, Research, Cell, Protein, Cytokine, Cytokine release syndrome, Patient, Manuscript, Risk, Tesi, TME, Interleukin, UCLA, Urology, Phase, Phenotype, IND, Natural killer T cell, Memory, Safety, International Society, Vaccine, Cancer, List of things named after Thomas Bayes, Medicine

The Company believes this is a critical breakthrough to avoid the complications associated with cytokine therapy and obtain NK cells ideally suited for attacking cancer.

Key Points: 
  • The Company believes this is a critical breakthrough to avoid the complications associated with cytokine therapy and obtain NK cells ideally suited for attacking cancer.
  • Using high-dimensional flow cytometry to simultaneously analyze 31 cell surface proteins, the team analyzed resting NK cells, IL-15 LAK (LAK=lymphokine activated killer cells), CIML-NK and INKmune-primed (TpNK) side-by-side.
  • The data showed at least 8 clusters of NK cell types, one of which was restricted to CIML-NK and TpNK.
  • CIML-NK contains a large population of terminally activated cells with loss of spare respiratory activity, which is absent from TpNK.

Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Wednesday, November 9, 2022
Adult, Interim, IL15, Risk, Sale, Population, G&A, CRS, Rituximab, Cryopreservation, B-cell lymphoma, Cash, Cell, MDS, Security (finance), Mab, Toxic shock syndrome, Neurotoxicity, SEC, Human, U.S. Securities and Exchange Commission, Cancer, AML, Research, Patient, ADCC, CEO, COVID-19, Private Securities Litigation Reform Act, Engineering, Acute myeloid leukemia, NKG2D, R, Antibody, MRD, Infection, CD19, GLOBE, Intellectual property, Tenant, Investment, Graft-versus-host disease, CAR, Safety, CRISPR, ClinicalTrials.gov, D, NK, Interleukin, Aplastic anemia, SITC, Vaccine, Pharmaceutical industry, Lease

Nkarta plans to present additional clinical data from its ongoing Phase 1 clinical trial of NKX019 by year-end 2022 as part of a company-hosted announcement.

Key Points: 
  • Nkarta plans to present additional clinical data from its ongoing Phase 1 clinical trial of NKX019 by year-end 2022 as part of a company-hosted announcement.
  • Nkarta plans to present additional clinical data from its ongoing Phase 1 clinical trial of NKX101 in the first half of 2023.
  • Nkarta updated this timing from year-end 2022 in order to collect a more robust and interpretable data set from a heavily pre-treated and heterogenous patient population.
  • Net Loss: Net loss was $28.3 million, or $0.58 per basic and diluted share, for the third quarter of 2022.

Catamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Interleukin 15, Engineering, Doctor of Philosophy, Transposable element, Tumor microenvironment, Immunosuppression, Annual general meeting, IL15, Immortalised cell line, Immunotherapy, Synthetic biology, Efficiency, CAR, RCC, CRISPR, Survival, SITC, Cas9, AML, CD70, Cell, MBA, Biotechnology, Society for Immunotherapy of Cancer, Treatment, Bio, Sofinnova, Hematological Cancer Research Investment and Education Act, Society, Sleeping Beauty transposon system, Catamaran, Vaccine, Medical imaging, Cancer, NK

Catamaran Bio , Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, today announced new data demonstrating preclinical efficacy of two CAR-NK cell therapies in solid and hematological cancers.

Key Points: 
  • Catamaran Bio , Inc., a biotechnology company developing off-the-shelf NK cell therapies to treat cancer, today announced new data demonstrating preclinical efficacy of two CAR-NK cell therapies in solid and hematological cancers.
  • Collectively, these preclinical data sets demonstrate the power of Catamarans fully-integrated TAILWIND platform to deliver allogeneic NK cell therapies for solid tumors, said Vipin Suri, PhD, MBA, Chief Scientific Officer of Catamaran Bio.
  • We have now shown preclinical efficacy in multiple xenograft models with two differentiated CAR-NK cell therapies engineered with the functional attributes necessary for durable efficacy in solid tumors and manufactured using an efficient non-viral cell engineering system.
  • Catamaran Bio is developing novel, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies designed to treat a broad range of cancers, including solid tumors.

Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

Retrieved on: 
Monday, May 16, 2022
Acute myeloid leukemia, Risk, Engineering, Hospital, Private Securities Litigation Reform Act, Cryopreservation, U.S. Securities and Exchange Commission, MDS, Doctor of Philosophy, Leadership, AML, Patient, Pediatric Hematology and Oncology, ClinicalTrials.gov, NHL, Interleukin, COVID-19, Adult, Cell, Â, Research, Jude the Apostle, SAN, Drug, Transplanter, Purdue University, NK, Intellectual property, CRISPR, IL15, Sale, Faculty, BMT, Johns Hopkins School of Medicine, Security (finance), CAR, SEC, Cancer, CD19, NKG2D, CEO, Interim, GLOBE, Pharmaceutical industry, Vaccine, MD

Shook will lead all clinical development and regulatory activities at Nkarta.

Key Points: 
  • Shook will lead all clinical development and regulatory activities at Nkarta.
  • We are excited to welcome David, a seasoned and valued member of Nkartas clinical team, to his new position.
  • In April 2022, Nkarta reported preliminary single-agent proof of concept data for its independent co-lead clinical programs, NKX101 and NKX019.
  • Prior to joining Nkarta in June 2020, he led multiple first-in-human cell therapy clinical trials, including CD19 CAR-NK and CD45RA-depleted BMT.

Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, May 12, 2022
Acute myeloid leukemia, MBA, Multiple myeloma, MRD, Risk, Population, R, Private Securities Litigation Reform Act, G&A, Toxic shock syndrome, Research, Cryopreservation, MDS, U.S. Securities and Exchange Commission, Exercise, Infection, AML, Patient, Investment, AACR, ClinicalTrials.gov, Cash, Therapy, NHL, Interleukin, Association, D, MPH, COVID-19, Graft-versus-host disease, Adult, Cell, DLBCL, NK, Intellectual property, CRISPR, American Association for Cancer Research, Board, IL15, Safety, CRS, Board of directors, Sale, Aplastic anemia, CRISPR Therapeutics, American Association, CAR, CD70, SEC, Cancer, CD19, Neurotoxicity, Security (finance), NKG2D, CEO, Interim, GLOBE, Pharmaceutical industry, Vaccine, Life insurance

In April 2022, Nkarta received approximately $215.5 millionin net proceeds from a public offering of its common stock.

Key Points: 
  • In April 2022, Nkarta received approximately $215.5 millionin net proceeds from a public offering of its common stock.
  • Cash and Cash Equivalents: As of March 31, 2022, Nkarta had cash, cash equivalents, restricted cash, and short-term investments of $219.1 million.
  • Non-cash stock-based compensation expense included in R&D expense was $1.9 million for the first quarter of 2022.
  • Net Loss: Net loss was $26.0 million, or $0.79 per basic and diluted share, for the first quarter of 2022.

ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, April 28, 2022
Biotechnology, Infectious Diseases, Health, Clinical Trials, Oncology, ASCO, U.S. Securities and Exchange Commission, Interleukin, Vaccine, GMP, Associate, Treatment of lung cancer, Patient, Infection, BCG, FDA, Annual general meeting, HIV, Private Securities Litigation Reform Act, COVID-19, American Society of Clinical Oncology, Food, Forward-looking statement, Disease, Clinical trial, CIS, 2021 Essex County Council election, DAMP, UCLA, IL15, NASDAQ, NMIBC, Society, SEC, Review, Immunotherapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, ImmunityBio, Urology

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today its abstracts were accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, in Chicago.

Key Points: 
  • ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced today its abstracts were accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, in Chicago.
  • ImmunityBio is a clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.
  • These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

Retrieved on: 
Monday, April 25, 2022
Patient, MDS, Clinical trial, IL15, U.S. Securities and Exchange Commission, Interleukin, Adult, Security (finance), NHL, ELN, Cryopreservation, ALL, Program, Cell, Cyclophosphamide, NKG2D, NCCN, AML, CD19, ClinicalTrials.gov, CAR, SEC, Forward-looking statement, Safety, NK, Risk, CRISPR, Interim, Cancer, Pharmaceutical industry, Vaccine

NKX101 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells engineered to target NKG2D ligands on cancer cells.

Key Points: 
  • NKX101 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells engineered to target NKG2D ligands on cancer cells.
  • NKX019 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells engineered to target the B-cell antigen CD19, a clinically validated target for B-cell cancer therapies.
  • NKX101 is an allogeneic, cryopreserved, off-the-shelf cancer immunotherapy candidate that uses natural killer (NK) cells derived from the peripheral blood of healthy donors.
  • Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients.